AptarGroup enters Phase II POSITS study as delivery partner for ENA Respiratory’s INNA-051 nasal spray
Aptar's UDS Powder system enters ENA Respiratory's POSITS Phase II trial. Analyse what INNA-051 must prove in 2026 and why the device choice matters. Read more.